NCT01688908Active, not recruiting
Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)
Effcacy of Endoscopic Screening for Esophageal Cancer in China (ESECC): a Population-based Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 23 Jan 2018
Brief summary (registry, in English)
To evaluate the efficacy of endoscopic screening on esophageal cancer (EC) and determine the most cost-effective strategy of endoscopic screening in high risk population in China, 668 villages of Hua county, a high risk area of esophageal cancer, were randomized into screening arm and control arm in a ratio of 1:1 and the total sample size is over 32,000 (\~16,000 per group). Participants in the screening arm will accept standard chromoendoscopy examination to detect early esophageal cancer and no screening were designed in the control arm. The incidence of advanced EC, EC-specific mortality and all-cause mortality will be compared within the two groups to test the hypothesis that endoscopic screening would alter the natural history of lesions in esophagus and the incidence of advanced stage EC, EC-specific mortality and all-cause mortality in the screening arm will be lower than the control group. Cost-effectiveness analysis will also be conducted to find the most cost-effective strategy of endoscopic screening in rural China.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 33948 (actual)
- First submitted
- 17 Sept 2012
- Start date
- 1 Jan 2012
- Primary completion date
- 31 Dec 2022
- Lead sponsor
- Peking University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT01688908
What you commit to
- Study type: Interventional
- Participants enrolled: 33948
- From 1 Jan 2012 to the primary completion date, 31 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Participants were eligible for the study if they meet the following criteria: 1) permanent residency in a target village; 2) age 45-69 (\>5 years of life expectancy), and no history of endoscopic examination within 5 years prior to the initial interview; 3) no history of cancer or mental disorder; 4) negative for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV); 5) voluntary participation and agreement to complete all phases of the examination.
Age in the registry: 45 years to 69 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Laboratory of genetics, Peking University cancer Hospital and institute Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
Related publications
- Effect of endoscopic screening for non-cardia gastric cancer: a 12-year report of a population-based randomized trial.BMC Med · 2026 · PMID 42410417
- Is random biopsy necessary for normal esophageal mucosa during chromoendoscopy? Evidence from a population-based cohort study.BMC Med · 2026 · PMID 41765898
- Evolving diagnostic and surveillance strategies in esophageal cancer screening: Evidence from population-based studies in China.Chin J Cancer Res · 2025 · PMID 41523838
- How should extra-large Lugol-unstained lesions of the esophagus be treated? Results from a population-based cohort study.Cancer Med · 2023 · PMID 37732496
- Absence of Lugol staining indicates initiation of esophageal squamous cell carcinoma: A combined genomic and epidemiologic study.Cell Rep Med · 2023 · PMID 37625408
This page is information, not medical advice. Discuss any trial with your doctor.